Sequential immunosuppressive therapy in progressive IgA nephropathy

Contributions to Nephrology

Volumn 157, Issue , 2007, Pages 109-113

  Rasche, Franz Maximilian ^a   Keller, Frieder ^a   Von Müller, Lutz ^a   Czock, David ^a   Lepper, Philipp M ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG PULSE THERAPY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; STEROIDS;

EID: 34249046033     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000102313     Document Type: Conference Paper

References (20)

1. Rasche FM, Klotz CH, Czock D, et al: Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003;93:131-136.
2. Pozzi C, Bolasco PG, Fogazzi GB, et al: Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-887.
3. Roccatello D, Ferro M, Cesano G, et al: Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000;15:833-835.
4. Tsuruya K, Harada A, Hirakata H, et al: Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 2000;53:1-9.
5. Ballardie FW, Roberts IS: Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002;13:142-148.
6. Goumenos DS, Davlouros P, El Nahas AM, et al: Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. Nephron Clin Pract 2003;93:58-68.
7. Tang S, Leung JC, Chan LY, et al: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68:802-812.
8. Maes BD, Oyen R, Claes K, et al: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-1849.
9. Frisch G, Lin J, Rosenstock J, et al: Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139-2145.
10. Rasche FM, Keller F, von Muller L, Sailer LK, Karges W, Czock D: Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. J Nephrol 2006;19:465-472.
11. Lee HS, Lee MS, Lee SM, et al: Histological grading of IgA nephropathy predicting renal outcome: revisiting H.S. Lee's glomerular grading system. Nephrol Dial Transplant 2005;20:342-348.
12. Haas M: Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997;29:829-842.
13. Poggio ED, Wang X, Greene T, et al: Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2004;22:22.
14. Jonsson CA, Carlsten H: Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003;3:31-37.
15. Colic M, Stojic-Vukanic Z, Pavlovic B, et al: Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003;134:63-69.
16. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
17. Pozzi C, Andrulli S, Del Vecchio L, et al: Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-163.
18. Komatsu H, Fujimoto S, Sato Y, et al: 'Point of no return (PNR)' in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. J Nephrol 2005;18:690-695.
19. D'Amico G, Ragni A, Gandini E, et al: Typical and atypical natural history of IgA nephropathy in adult patients. Contrib Nephrol 1993;104:6-13.
20. Scholl U, Wastl U, Risler T, et al: The 'point of no return' and the rate of progression in the natural history of IgA nephritis. Clin Nephrol 1999;52:285-292.